Dupilumab significantly reduced airway inflammation in patients with uncontrolled, moderate-to-severe type 2 asthma. Read now.

Researchers found increased odds for clinical remission on dupilumab with high blood eosinophil and fractional exhaled nitric ...

Reslizumab may also prove to be efficacious in patients with a similar asthma phenotype. Dual inhibition of IL-4 and IL-13 with dupilumab represents a very promising avenue for biologic-based ...

and Sanofi today presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent ® (dupilumab) in adults with moderate-to-severe bullous ...

Tezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also decreasing need for ...

Discover a proof-of-concept study that was conducted to explore whether dupilumab could induce desensitisation to peanut.

Biologic treatment for atopic dermatitis appeared to improve growth trajectories for younger children, a trial analysis ...

1 Dupilumab is being jointly developed by Regeneron ... or inhaled corticosteroid medicines; have asthma and use an asthma medicine; or have atopic dermatitis, chronic rhinosinusitis with nasal ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP) Regeneron Pharmaceuticals, Inc. Tue, Feb 18, 2025, 12:59 AM 13 min read ...